DEXYCU
Total Payments
$1.7M
Transactions
3,680
Doctors
1,839
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $98,575 | 9 | 0 |
| 2023 | $115,615 | 7 | 0 |
| 2022 | $225,814 | 612 | 411 |
| 2021 | $224,058 | 888 | 588 |
| 2020 | $574,690 | 619 | 357 |
| 2019 | $418,467 | 1,545 | 905 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $886,086 | 56 | 53.5% |
| Consulting Fee | $559,701 | 285 | 33.8% |
| Food and Beverage | $133,945 | 3,263 | 8.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $72,150 | 51 | 4.4% |
| Travel and Lodging | $5,194 | 21 | 0.3% |
| Education | $144.29 | 4 | 0.0% |
Payments by Type
Research
$886,086
56 transactions
General
$771,134
3,624 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1% | EyePoint Pharmaceuticals US, Inc. | $227,785 | 0 |
| DEXYCU Retrospective study | EyePoint Pharmaceuticals US, Inc. | $111,070 | 1 |
| A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract | EyePoint Pharmaceuticals US, Inc. | $98,575 | 0 |
| Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract (EYP-DIP-001) | EyePoint Pharmaceuticals US, Inc. | $91,935 | 0 |
| Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract | EyePoint Pharmaceuticals US, Inc. | $88,615 | 0 |
| Effect of Intraoperative Dexamethasone on Post-Op Dry Eye | EyePoint Pharmaceuticals US, Inc. | $57,500 | 0 |
| Effect of Intraoperative Dexamethasone on Post-op Dry Eye | EyePoint Pharmaceuticals US, Inc. | $40,000 | 0 |
| Retrospective Review of Dexamethasone Intracameral Drug-Delivery Suspension for Inflammation Associated with Vitreoretinal Surgery | EyePoint Pharmaceuticals US, Inc. | $28,245 | 0 |
| A Prospective Study of the Efficacy of Intracameral Dexamethasone (Dexycu) Compared to Standard of Care Treatment for Post-Cataract Surgical Pain and Anterior Chamber Inflammation | EyePoint Pharmaceuticals US, Inc. | $27,000 | 0 |
| Prospective Study Comparing Intravitreal Versus Posterior Chamber Dexycu Administration Following Cataract and Glaucoma Surgery | EyePoint Pharmaceuticals US, Inc. | $25,105 | 0 |
| Prospective Study Comparing Intrvitreal Versus Posterior Chamber Dexycu Administration Following Cataract and Glaucoma Surgery | EyePoint Pharmaceuticals US, Inc. | $25,105 | 0 |
| A Prospective Study of the Efficacy of Dexycu compared to Standard of Care Treatment for Post-Surgical Pain and Anterior Chamber Inflammation | EyePoint Pharmaceuticals US, Inc. | $25,000 | 0 |
| Retrospective Review of Dexamethasone Intracameral Drug-Delivery Suspension for Inflammation Associated with Vitreoretinal Surgery: Analysis of Macular Thickness | EyePoint Pharmaceuticals US, Inc. | $24,150 | 0 |
| Pending Registration: Retrospective Review of Dexamethasone Intracameral Drug Delivery Suspension for Inflammation Associated with Vitreoretinal Surgery | EyePoint Pharmaceuticals US, Inc. | $14,000 | 0 |
| A phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to evaluate the safety of DEXYCU for the treatment of inflammation following ocular surgery for childhood cataract | EyePoint Pharmaceuticals US, Inc. | $2,000 | 0 |
Top Doctors Receiving Payments for DEXYCU
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Baldwin, NY | $883,606 | 55 |
| David Guyer | Ophthalmology | New York, NY | $82,449 | 5 |
| , MD | Ophthalmology | Cincinnati, OH | $79,557 | 16 |
| , MD | Ophthalmology | Pennington, NJ | $78,980 | 35 |
| , M.D | Ophthalmology | Laguna Hills, CA | $43,614 | 35 |
| , MD | Cornea and External Diseases Specialist | Smithtown, NY | $41,853 | 54 |
| , MD | Ophthalmology | Petaluma, CA | $33,192 | 23 |
| , MD | Ophthalmology | Washington, MO | $26,982 | 4 |
| , MD | Ophthalmology | Largo, FL | $19,906 | 20 |
| , MD | Ophthalmology | Lake Villa, IL | $16,912 | 31 |
| , M.D | Ophthalmology | New York, NY | $16,705 | 30 |
| Inder Singh | Ophthalmology | Racine, WI | $16,134 | 26 |
| , M.D | Ophthalmology | Bradenton, FL | $13,050 | 16 |
| , MD | Ophthalmology | Springfield, IL | $10,365 | 19 |
| , MD | Ophthalmology | Kansas City, MO | $9,656 | 15 |
| , M.D | Ophthalmology | Jenkintown, PA | $8,194 | 13 |
| , MD | Ophthalmology | Sonoma, CA | $8,011 | 15 |
| , MD | Ophthalmology | Atlanta, GA | $7,102 | 12 |
| , M.D | Ophthalmology | Tarpon Springs, FL | $6,629 | 9 |
| , MD | Ophthalmology | Des Plaines, IL | $5,249 | 13 |
| , M.D | Ophthalmology | Newport Beach, CA | $5,118 | 9 |
| , MD | Ophthalmology | Bala Cynwyd, PA | $4,642 | 12 |
| , OD | Optometrist | Lexington, KY | $4,250 | 2 |
| , MD | Ophthalmology | Rockville Centre, NY | $4,100 | 22 |
| , MD | Ophthalmology | Greensboro, NC | $3,975 | 6 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $1.7M
- Total Doctors 1,839
- Transactions 3,680
About DEXYCU
DEXYCU is a drug associated with $1.7M in payments to 1,839 healthcare providers, recorded across 3,680 transactions in the CMS Open Payments database. The primary manufacturer is EyePoint Pharmaceuticals US, Inc..
Payment data is available from 2019 to 2024. In 2024, $98,575 was paid across 9 transactions to 0 doctors.
The most common payment nature for DEXYCU is "Unspecified" ($886,086, 53.5% of total).
DEXYCU is associated with 15 research studies, including "A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%" ($227,785).